Major financial institutions, including Bank of America and Royal Bank of Canada, engaged in required 13F filings and saw analyst rating adjustments.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major financial institutions, including Bank of America and Royal Bank of Canada, engaged in required 13F filings and saw analyst rating adjustments.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Bank of America lifted its price objective and issued a 'buy' rating for BridgeBio Pharma, concurrent with a required institutional investment filing.Sub-event
Multiple financial institutions reported 13F filings and saw analyst rating changes.1 source
Keep exploring
The entities involved
-
Bank of America
American multinational banking and financial services corporation
-
Royal Bank of Canada
financial institution in Canada
-
SEC
Slovak company
Related events
- Bank of America and Bank of New York are involved in market activities, including analyst target price increases and required 13F filings with the SEC.
- Financial institutions, including Citigroup and RBC, filed 13F reports and adjusted analyst ratings with the SEC.
- Financial institutions, including RBC and Truist, filed 13F reports and adjusted price targets with the SEC.
- Analyst raised price target and gave outperform rating for Aramark on August 19, 2026.
- Ionis Pharmaceuticals filed institutional investment disclosures and received analyst rating coverage on August 30, 2026.